Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | POLE inact mut |
| Therapy | unspecified immune checkpoint inhibitor |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| POLE inact mut | Advanced Solid Tumor | predicted - sensitive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, treatment with immune checkpoint inhibitors including PD1/PD-L1 inhibitor monotherapies or in combination with CTLA inhibitors resulted in improved clinical benefit rate (82.4% vs 30.0%, p=0.013), median progression-free survival (15.1 vs 2.2 mo, p<0.001), overall survival (29.5 vs 6.8 mo, p<0.001), and treatment duration (15.5 vs 2.5 mo, p<0.001) in advanced solid tumor patients harboring pathogenic POLE mutations compared to those harboring benign mutations (PMID: 35108036). | 35108036 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35108036) | Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. | Full reference... |